Dong-A ST Achieves Therapeutic Equivalence With Stelara Biosimilar
Company Aims To Submit EU and US Marketing Authorization During H1
Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.
